Mirikizumab (LY3074828)

Mirikizumab is a biologic being tested in people with psoriasis.

Mechanism Primary

anti-inflammatory

Phase

Indication

Psoriasis

Therapeutic Approach

Mirikizumab is taken as an injection.

Manufacturer

Eli Lilly

Manufacturer URL

Link To Trial Page

Link To Past Trial Page

Mechanism Secondary

IL-23 inhibitor

Drug Type